{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:29:35Z","timestamp":1794666575430,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"This work was supported by the Mary Lake Polan Gynecologic Oncology Endowment for Research (O.D.), the Vivian Scott Fellowship in Gynecologic Oncology (O.D.)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,10,5]]},"DOI":"10.1038\/s41416-022-01887-3","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T15:03:26Z","timestamp":1656083006000},"page":"1026-1033","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Macrophage-derived CCL23 upregulates expression of T-cell exhaustion markers in ovarian cancer"],"prefix":"10.1038","volume":"127","author":[{"given":"Kalika","family":"Kamat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9292-4515","authenticated-orcid":false,"given":"Venkatesh","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1976-5201","authenticated-orcid":false,"given":"Oliver","family":"Dorigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"key":"1887_CR1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3389\/fonc.2020.01204","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang Y, Ren F, Song Z, Wang X, Zhang C, Ouyang L. PARP inhibitors in patients with newly diagnosed advanced ovarian cancer: a meta-analysis of randomized clinical trials. Front Oncol. 2020;10:1204.","journal-title":"Front Oncol"},{"key":"1887_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/diagnostics10030146","volume":"10","author":"F Borella","year":"2020","unstructured":"Borella F, Ghisoni E, Giannone G, Cosma S, Benedetto C, Valabrega G, et al. Immune checkpoint inhibitors in epithelial ovarian cancer: an overview on efficacy and future perspectives. Diagnostics. 2020;10:146.","journal-title":"Diagnostics."},{"key":"1887_CR3","doi-asserted-by":"publisher","first-page":"E242","DOI":"10.3390\/cancers10080242","volume":"10","author":"GM Rodriguez","year":"2018","unstructured":"Rodriguez GM, Galpin KJC, McCloskey CW, Vanderhyden BC. The tumor microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy. Cancers. 2018;10:E242.","journal-title":"Cancers"},{"key":"1887_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2017.07.025","volume":"170","author":"A Jimenez-Sanchez","year":"2017","unstructured":"Jimenez-Sanchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, et al. Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell. 2017;170:927\u201338. e20","journal-title":"Cell."},{"key":"1887_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.ygyno.2018.01.014","volume":"149","author":"V Krishnan","year":"2018","unstructured":"Krishnan V, Schaar B, Tallapragada S, Dorigo O. Tumor associated macrophages in gynecologic cancers. Gynecol Oncol. 2018;149:205\u201313.","journal-title":"Gynecol Oncol"},{"key":"1887_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/imt-2016-0135","volume":"9","author":"AJ Petty","year":"2017","unstructured":"Petty AJ, Yang Y. Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy. 2017;9:289\u2013302.","journal-title":"Immunotherapy."},{"key":"1887_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang X, Wang J, Lu D, Xu X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther. 2021;6:75.","journal-title":"Signal Transduct Target Ther"},{"key":"1887_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-7-19","volume":"7","author":"M Zhang","year":"2014","unstructured":"Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, et al. A high M1\/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res. 2014;7:19.","journal-title":"J Ovarian Res"},{"key":"1887_CR9","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/PGP.0b013e318284e198","volume":"32","author":"EC Dun","year":"2013","unstructured":"Dun EC, Hanley K, Wieser F, Bohman S, Yu J, Taylor RN. Infiltration of tumor-associated macrophages is increased in the epithelial and stromal compartments of endometrial carcinomas. Int J Gynecol Pathol. 2013;32:576\u201384.","journal-title":"Int J Gynecol Pathol"},{"key":"1887_CR10","doi-asserted-by":"publisher","first-page":"e0136654","DOI":"10.1371\/journal.pone.0136654","volume":"10","author":"M Petrillo","year":"2015","unstructured":"Petrillo M, Zannoni GF, Martinelli E, Pedone Anchora L, Ferrandina G, Tropeano G, et al. Polarisation of tumor-associated macrophages toward M2 phenotype correlates with poor response to chemoradiation and reduced survival in patients with locally advanced cervical cancer. PLoS ONE. 2015;10:e0136654.","journal-title":"PLoS ONE"},{"key":"1887_CR11","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s42003-020-01246-z","volume":"3","author":"V Krishnan","year":"2020","unstructured":"Krishnan V, Tallapragada S, Schaar B, Kamat K, Chanana AM, Zhang Y, et al. Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1. Commun Biol. 2020;3:524.","journal-title":"Commun Biol"},{"key":"1887_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jaci.2011.03.017","volume":"128","author":"JA Poposki","year":"2011","unstructured":"Poposki JA, Uzzaman A, Nagarkar DR, Chustz RT, Peters AT, Suh LA, et al. Elevated expression of CC Chemokine ligand 23 in eosinophilic chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2011;128:73\u201381. e4","journal-title":"J Allergy Clin Immunol"},{"key":"1887_CR13","doi-asserted-by":"crossref","unstructured":"Arruda-Silva F, Bianchetto-Aguilera F, Gasperini S, Polletti S, Cosentino E, Tamassia N, et al. Human neutrophils produce CCL23 in response to various TLR-agonists and TNF\u03b1. Front Cell Infect Microbiol. 2017;7:176.","DOI":"10.3389\/fcimb.2017.00176"},{"key":"1887_CR14","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.4049\/jimmunol.178.7.4335","volume":"178","author":"H Novak","year":"2007","unstructured":"Novak H, M\u00fcller A, Harrer N, G\u00fcnther C, Carballido JM, Woisetschl\u00e4ger M. CCL23 expression is induced by IL-4 in a STAT6-dependent fashion. J Immunol. 2007;178:4335\u201341.","journal-title":"J Immunol"},{"key":"1887_CR15","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11030-008-9076-x","volume":"12","author":"JF Cheng","year":"2008","unstructured":"Cheng JF, Jack R. CCR1 antagonists. Mol Divers. 2008;12:17\u201323.","journal-title":"Mol Divers"},{"key":"1887_CR16","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.4049\/jimmunol.162.7.3840","volume":"162","author":"RL Rabin","year":"1999","unstructured":"Rabin RL, Park MK, Liao F, Swofford R, Stephany D, Farber JM. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. J Immunol. 1999;162:3840\u201350.","journal-title":"J Immunol"},{"key":"1887_CR17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.cyto.2005.01.018","volume":"30","author":"J Hwang","year":"2005","unstructured":"Hwang J, Son KN, Kim CW, Ko J, Na DS, Kwon BS, et al. Human CC chemokine CCL23, a ligand for CCR1, induces endothelial cell migration and promotes angiogenesis. Cytokine. 2005;30:254\u201363.","journal-title":"Cytokine."},{"key":"1887_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.trim.2016.05.003","volume":"38","author":"F Foroughi","year":"2016","unstructured":"Foroughi F, Amirzargar A, Ahmadpoor P, Noorbakhsh F, Nafar M, Yekaninejad MS, et al. Increased levels of CD4(+) and CD8(+) T cells expressing CCR1 in patients developing allograft dysfunction; a cohort study. Transpl Immunol. 2016;38:67\u201374.","journal-title":"Transpl Immunol"},{"key":"1887_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/icb.2016.26","volume":"94","author":"MJ Conroy","year":"2016","unstructured":"Conroy MJ, Galvin KC, Kavanagh ME, Mongan AM, Doyle SL, Gilmartin N, et al. CCR1 antagonism attenuates T cell trafficking to omentum and liver in obesity-associated cancer. Immunol Cell Biol. 2016;94:531\u20137.","journal-title":"Immunol Cell Biol"},{"key":"1887_CR20","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.cyto.2009.12.010","volume":"50","author":"J Kim","year":"2010","unstructured":"Kim J, Kim YS, Ko J. CK\u03b28\/CCL23 and its isoform CK\u03b28-1 induce up-regulation of cyclins via the Gi\/Go protein\/PLC\/PKC\u03b4\/ERK leading to cell-cycle progression. Cytokine. 2010;50:42\u20139.","journal-title":"Cytokine."},{"key":"1887_CR21","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.bbrc.2005.12.037","volume":"340","author":"KN Son","year":"2006","unstructured":"Son KN, Hwang J, Kwon BS, Kim J. Human CC chemokine CCL23 enhances expression of matrix metalloproteinase-2 and invasion of vascular endothelial cells. Biochem Biophys Res Commun. 2006;340:498\u2013504.","journal-title":"Biochem Biophys Res Commun"},{"key":"1887_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.bbrc.2009.02.149","volume":"382","author":"KY Han","year":"2009","unstructured":"Han KY, Kim CW, Lee TH, Son Y, Kim J. CCL23 up-regulates expression of KDR\/Flk-1 and potentiates VEGF-induced proliferation and migration of human endothelial cells. Biochem Biophys Res Commun. 2009;382:124\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"1887_CR23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37:773\u201382.","journal-title":"Nat Biotechnol"},{"key":"1887_CR24","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.immuni.2016.01.018","volume":"44","author":"A Taylor","year":"2016","unstructured":"Taylor A, Harker JA, Chanthong K, Stevenson PG, Zuniga EI, Rudd CE. Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of co-receptor PD-1 to enhance CD8(+) cytolytic T cell responses. Immunity. 2016;44:274\u201386.","journal-title":"Immunity."},{"key":"1887_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","volume":"12","author":"Y Lin","year":"2019","unstructured":"Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12:76.","journal-title":"J Hematol Oncol"},{"key":"1887_CR26","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942\u20139.","journal-title":"Nat Med"},{"key":"1887_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fonc.2020.00188","volume":"10","author":"J Zhou","year":"2020","unstructured":"Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou X. Tumor-associated macrophages: recent insights and therapies. Front Oncol. 2020;10:188.","journal-title":"Front Oncol"},{"key":"1887_CR28","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1681\/ASN.2009060592","volume":"21","author":"Q Cao","year":"2010","unstructured":"Cao Q, Wang Y, Zheng D, Sun Y, Wang Y, Lee VW, et al. IL-10\/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. J Am Soc Nephrol. 2010;21:933\u201342.","journal-title":"J Am Soc Nephrol"},{"key":"1887_CR29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1365-2567.2006.02321.x","volume":"117","author":"A Taylor","year":"2006","unstructured":"Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology. 2006;117:433\u201342.","journal-title":"Immunology."},{"key":"1887_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","volume":"26","author":"Y Chen","year":"2019","unstructured":"Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26:78.","journal-title":"J Biomed Sci"},{"key":"1887_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.canlet.2019.03.040","volume":"452","author":"D Wang","year":"2019","unstructured":"Wang D, Yang L, Yue D, Cao L, Li L, Wang D, et al. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion. Cancer Lett. 2019;452:244\u201353.","journal-title":"Cancer Lett"},{"key":"1887_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/ijc.28335","volume":"134","author":"S Reinartz","year":"2014","unstructured":"Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, et al. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 2014;134:32\u201342.","journal-title":"Int J Cancer"},{"key":"1887_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10456-013-9381-6","volume":"17","author":"N Jetten","year":"2014","unstructured":"Jetten N, Verbruggen S, Gijbels MJ, Post MJ, De Winther MP, Donners MM. Anti-inflammatory M2, but not pro-inflammatory M1 macrophages promote angiogenesis in vivo. Angiogenesis. 2014;17:109\u201318.","journal-title":"Angiogenesis."},{"key":"1887_CR34","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/(SICI)1097-4652(200005)183:2<196::AID-JCP6>3.0.CO;2-8","volume":"183","author":"BJ Votta","year":"2000","unstructured":"Votta BJ, White JR, Dodds RA, James IE, Connor JR, Lee-Rykaczewski E, et al. CKbeta-8 [CCL23], a novel CC chemokine, is chemotactic for human osteoclast precursors and is expressed in bone tissues. J Cell Physiol. 2000;183:196\u2013207.","journal-title":"J Cell Physiol"},{"key":"1887_CR35","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.exphem.2005.06.028","volume":"33","author":"CH Shih","year":"2005","unstructured":"Shih CH, van Eeden SF, Goto Y, Hogg JC. CCL23\/myeloid progenitor inhibitory factor-1 inhibits production and release of polymorphonuclear leukocytes and monocytes from the bone marrow. Exp Hematol. 2005;33:1101\u20138.","journal-title":"Exp Hematol"},{"key":"1887_CR36","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.lfs.2009.11.012","volume":"86","author":"J Kim","year":"2010","unstructured":"Kim J, Kim YS, Ko J. CK beta 8\/CCL23 induces cell migration via the Gi\/Go protein\/PLC\/PKC delta\/NF-kappa B and is involved in inflammatory responses. Life Sci. 2010;86:300\u20138.","journal-title":"Life Sci"},{"key":"1887_CR37","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1002\/art.23667","volume":"58","author":"I Rioja","year":"2008","unstructured":"Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum. 2008;58:2257\u201367.","journal-title":"Arthritis Rheum"},{"key":"1887_CR38","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1089\/jir.2009.0045","volume":"30","author":"L Castillo","year":"2010","unstructured":"Castillo L, Rohatgi A, Ayers CR, Owens AW, Das SR, Khera A, et al. Associations of four circulating chemokines with multiple atherosclerosis phenotypes in a large population-based sample: results from the Dallas heart study. J Interferon Cytokine Res. 2010;30:339\u201347.","journal-title":"J Interferon Cytokine Res"},{"key":"1887_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jaci.2011.03.017","volume":"128","author":"JA Poposki","year":"2011","unstructured":"Poposki JA, Uzzaman A, Nagarkar DR, Chustz RT, Peters AT, Suh LA, et al. Increased expression of the chemokine CCL23 in eosinophilic chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2011;128:73\u201381.","journal-title":"J Allergy Clin Immunol"},{"key":"1887_CR40","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00403-010-1078-8","volume":"303","author":"K Yanaba","year":"2011","unstructured":"Yanaba K, Yoshizaki A, Muroi E, Ogawa F, Asano Y, Kadono T, et al. Serum CCL23 levels are increased in patients with systemic sclerosis. Arch Dermatol Res. 2011;303:29\u201334.","journal-title":"Arch Dermatol Res"},{"key":"1887_CR41","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/joim.12738","volume":"283","author":"A Simats","year":"2018","unstructured":"Simats A, Garcia-Berrocoso T, Penalba A, Giralt D, Llovera G, Jiang Y, et al. CCL23: a new CC chemokine involved in human brain damage. J Intern Med. 2018;283:461\u201375.","journal-title":"J Intern Med"},{"key":"1887_CR42","doi-asserted-by":"publisher","first-page":"102555","DOI":"10.1016\/j.isci.2021.102555","volume":"24","author":"L Steele","year":"2021","unstructured":"Steele L, Mannion AJ, Shaw G, Maclennan KA, Cook GP, Rudd CE, et al. Non-redundant activity of GSK-3\u03b1 and GSK-3\u03b2 in T cell-mediated tumor rejection. iScience. 2021;24:102555.","journal-title":"iScience"},{"key":"1887_CR43","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.celrep.2020.01.076","volume":"30","author":"CE Rudd","year":"2020","unstructured":"Rudd CE, Chanthong K, Taylor A. Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity. Cell Rep. 2020;30:2075\u201382.","journal-title":"Cell Rep."},{"key":"1887_CR44","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1172\/JCI46102","volume":"121","author":"L Baitsch","year":"2011","unstructured":"Baitsch L, Baumgaertner P, Dev\u00eavre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J Clin Invest. 2011;121:2350\u201360.","journal-title":"J Clin Invest"},{"key":"1887_CR45","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/2326-6066.CIR-15-0097","volume":"3","author":"DS Thommen","year":"2015","unstructured":"Thommen DS, Schreiner J, M\u00fcller P, Herzig P, Roller A, Belousov A, et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res. 2015;3:1344\u201355.","journal-title":"Cancer Immunol Res"},{"key":"1887_CR46","doi-asserted-by":"publisher","first-page":"142513","DOI":"10.1172\/jci.insight.142513","volume":"6","author":"C-C Balan\u00e7a","year":"2021","unstructured":"Balan\u00e7a C-C, Salvioni A, Scarlata C-M, Michelas M, Martinez-Gomez C, Gomez-Roca C, et al. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells. JCI Insight. 2021;6:142513.","journal-title":"JCI Insight"},{"key":"1887_CR47","doi-asserted-by":"publisher","first-page":"e7375947","DOI":"10.1155\/2020\/7375947","volume":"2020","author":"E Foord","year":"2020","unstructured":"Foord E, Klynning C, Schoutrop E, F\u00f6rster JM, Krieg J, M\u00f6rtberg A, et al. Profound functional suppression of tumor-infiltrating T-cells in ovarian cancer patients can be reversed using PD-1-blocking antibodies or DARPin\u00ae proteins. J Immunol Res. 2020;2020:e7375947.","journal-title":"J Immunol Res"},{"key":"1887_CR48","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.cell.2018.03.073","volume":"173","author":"AW Zhang","year":"2018","unstructured":"Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, et al. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer. Cell 2018;173:1755\u201369. e22","journal-title":"Cell"},{"key":"1887_CR49","doi-asserted-by":"publisher","first-page":"109165","DOI":"10.1016\/j.celrep.2021.109165","volume":"35","author":"S Olalekan","year":"2021","unstructured":"Olalekan S, Xie B, Back R, Eckart H, Basu A. Characterizing the tumor microenvironment of metastatic ovarian cancer by single-cell transcriptomics. Cell Rep. 2021;35:109165.","journal-title":"Cell Rep."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01887-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01887-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01887-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T06:12:47Z","timestamp":1675923167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01887-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,10,5]]}},"alternative-id":["1887"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01887-3","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"assertion":[{"value":"15 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KK and VK have no competing interests. OD has served on Advisory Boards for Merck, Eisai, PACT, GSK, IMV, Genentech. OD received funding for clinical research from AstraZeneca, IMV, Millenium, Pharmamar, Genentech, Bioeclipse.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Patient samples were collected under an approved Institutional Review Board (IRB) protocol at Stanford University and the University of Pennsylvania. Informed consent for healthy plasma was obtained by Innovative Research (Novi, MI). This study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}